The Obesity Action Coalition (OAC) is urging Starbucks to change course on a reported plan to discontinue health plan coverage of GLP-1 medications for obesity. Health advocates fear that withdrawing coverage of these prescriptions could affect essential care for individuals living with obesity.

Rhythm Pharmaceuticals announces promising results from their Phase 3 TRANSCEND trial, where setmelanotide significantly reduced BMI in patients with acquired hypothalamic obesity. This breakthrough offers new hope for treating this rare condition resulting from hypothalamic damage.